Trial Profile
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Mosunetuzumab (Primary) ; Mosunetuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Bendamustine; Rituximab; Tocilizumab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 04 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Jan 2024 Results (n=120) assessing safety and efficacy of Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma published in the Nature Medicine
- 12 Dec 2023 Results( As of October 27, 2022, n=20 pts) reporting initial safety and efficacy data from an ongoing Phase II expansion cohort of pts with R/R MCL who had received prior BTKi therapy,presented at the 65th American Society of Hematology Annual Meeting and Exposition